To assess the clinical significance of DNA2 in patients with mutant TP53-harboring cancers, we focused our data mining analysis on ovarian cancer as it is the cancer type with the most prevalent somatic TP53 mutations. This evidence concerns the gene TP53 and ovarian carcinoma.